Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting

Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting




Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced an oral presentation on RBN-2397 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 4 to 8, 2021. The full meeting program is available at: www.asco.org.

Abstract Title: A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors

Session Date & Time: Friday, June 4, 2021 at 11:00 AM ET

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract ID: 3000

About RBN-2397

RBN-2397, is an orally available small molecule inhibitor of PARP7 that we are developing for the treatment of solid tumors. PARP7 is upregulated in response to cellular stress, including genomic instability in cancers, and acts as a brake on the cellular stress response by negatively regulating the Type I interferon response. By inhibiting PARP7 in tumor cells, RBN-2397 has been shown to directly inhibit cellular proliferation and restore interferon signaling to stimulate an innate and adaptive antitumor immune response. RBN-2397 is currently in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors. PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung, or SCCL, which represents approximately 30% of all non-small cell lung cancers.

About Ribon Therapeutics

Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+–utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts. For more information visit www.RibonTx.com.

Contacts

Brendan Burns

Argot Partners

212.600.1902

Ribon@argotpartners.com